3T Biosciences announced the appointment of Rebeca Villarreal-Barragan, MBA, as Head of Clinical Operations to lead clinical operations for its TCR-based therapeutics pipeline targeting solid tumors.15
Villarreal-Barragan has experience from Gilead Sciences, Kite Pharma, T-Knife Therapeutics, and Achilles Therapeutics in delivering first-in-human and biomarker-driven oncology trials.1
She holds an MBA from the University of Buckingham and a bachelor’s degree in biotechnology from the Monterrey Institute of Technology.1
The announcement was made on March 2, 2026, as per Business Wire and the company's news page.15
3T Biosciences develops T-cell engager therapeutics using its 3T-TRACE™ platform for cancer and immune-related diseases.1
Sources:
1. https://www.businesswire.com/news/home/20260302945362/en/3T-Biosciences-Appoints-Rebeca-Villarreal-Barragan-MBA-as-Head-of-Clinical-Operations